When the Data Comes Home
We're in Boulder, which means the biggest study yet of legal psilocybin didn't come from a lab across the country. It came from down the road. Researchers at the University of Colorado School of Medicine took the intake and follow-up surveys from thousands of real sessions at licensed service centers in Colorado and Oregon and turned them into the largest real-world look at regulated psilocybin services anyone has published.
(Thompson et al., "Real-world use, safety, and mental health efficacy of regulated psilocybin services in Oregon and Colorado," medRxiv, 2026. A preprint — posted, not yet peer-reviewed.)
We make a quiet box for growing gourmet and culinary mushrooms on your counter. We are never going to make, sell, or tell you how to grow the species in this study — that's the product line we don't cross. But covering the fungal world honestly is our whole job, and this is our state's own data, so let's read it the way it deserves to be read: neither as a miracle nor as a headline, but as a real, imperfect measurement.
What they found
Across 2,363 people, two weeks after a dose, depression scores (the PHQ-9) fell about 49%, anxiety scores (the GAD-7) fell about 51%, and well-being (the WHO-5) rose about 22%. Roughly half the depression and anxiety, gone at the two-week mark.
Doses ran from 1 to 95 mg, averaging around 29 mg. And here's the finding that should reorder some assumptions: sessions above 30 mg did not beat sessions at or below 30 mg on symptom change. More was not better. That's the opposite of how most people talk about these experiences, and it's exactly the kind of thing you only learn by counting thousands of them instead of chasing the most dramatic ones.
The small print, which is the actual story
A number that big and that good deserves suspicion, so let's give it some — the honest kind, not the dismissive kind.
This is not a clinical trial. There was no placebo group, no control, no randomization. It's a snapshot of people who chose to go, paid to go, and answered surveys before and after. People who seek out a psilocybin session expect to feel better, the setting is designed to help them feel better, and the ones who felt worse are less likely to fill out the second survey. All of that inflates a two-week number. So read the improvements as what happened in the real world, not as proof the molecule did it. Those are different claims, and the difference matters.
Two weeks is not a life. Everyone involved says so plainly — including the authors, who call the long-term outcomes the next study. A feeling two weeks out is real. It is not the same as a change that holds at six months.
And the part no honest summary gets to skip: most of the reported harms were mild, but a small number of people with no prior history reported new suicidal thoughts after their session. Five more serious events were noted, not clearly tied to the treatment. This is a real signal, and the right response to it is more attention, not less — better screening, better aftercare, someone checking in on the days after. A drug that helps most people and hurts a few is not a miracle and not a menace. It's a medicine, and medicines get handled carefully or they get handled badly.
Why a mushroom grower should sit with this
The thing that keeps surfacing in this newsletter is that the value of these organisms was never only in a molecule. This study, sideways, says the same thing. If more milligrams don't buy more benefit, then whatever is doing the work isn't just chemistry by the gram. It's set, setting, intention, aftercare — the attention around the experience, not merely the dose inside it.
That should sound familiar if you've ever stood at your counter waiting five days for a flush and caught it at its peak. The lesson of growing anything alive is that outcomes come from attention, timing, and care, not from turning a dial to maximum. Colorado just measured a version of that at scale, in a very different fungus, with real stakes attached.
Where we stand
We grow food. We think fungi are the most interesting kingdom alive, and when the frontier of that kingdom shows up in our own backyard, we're going to tell you what it says — and what it doesn't. Psilocybin services are legal only through licensed facilitators in Oregon and Colorado, this is a preprint reporting two-week results, and nothing here is medical advice. Covering it honestly is our job. Making it is not.
The data came home this week. It's better news than the skeptics expected and more careful news than the evangelists want. That middle — hopeful, measured, watching the ones it might hurt — is exactly where a mushroom person should be comfortable standing.
First Flush Friday is a weekly newsletter from Sh-Room about growing mushrooms at home. We cover the science and culture of the whole fungal kingdom. We make a countertop incubator for gourmet and culinary species only. Free, every Friday, unsubscribe anytime. sh-room.com/first-flush-friday